Liquid biopsy - emergence of a new era in personalized cancer care

Abraham, Jessy; Singh, Sunita; Joshi, Shalaka

doi:10.1186/s41241-018-0053-0

Cited by 4 publications

(8 citation statements)

References 156 publications

(182 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Insufficient tissue specimens, for example because of inaccessible tumor location or late presentation with metastases at diagnosis, limit the available diagnostic testing options. 54 For example, patients with lung cancer, particularly small cell lung cancer, are typically diagnosed through cytologic material only. 55,56 However, large cell carcinomas of the lung cannot be identified with small biopsy or cytology specimens, and their diagnosis requires an invasive resection specimen.…”

mentioning

confidence: 99%

Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis

Ascierto

Bifulco

Palmieri

et al. 2019

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

it.An enduring goal of personalized medicine in cancer is the ability to identify patients who are likely to respond to specific therapies. Our growing understanding of the biology and molecular signatures of individual tumor types has facilitated the identification of predictive biomarkers and has led to an increasing number of diagnostic tests to be performed, often as serial and distinct assays on limited tumor specimens. The biomarker diagnostics field has been revolutionized by next-generation sequencing (NGS), which provides a comprehensive overview of the genomic profile of a tumor. Many preanalytic variables can influence the accuracy and reliability of NGS results. Standardization of preanalytic variables is, however, complicated by the plethora of specimen acquisition and processing methods. Variables across the tissue journey, including specimen acquisition, specimen fixation, and sectioning, as well as postfixation processing, such as nucleic acid extraction, library preparation, and choice of sequencing methods, are critical for the reliability of NGS analysis; thus, standardization would be beneficial. In this article, each step in the tissue journey is outlined, with specific focus on preanalytic variables that can influence NGS results. Practical considerations for standardization of these variables are provided to facilitate accurate, reliable, and reproducible NGS-based molecular characterization of tumors, ultimately informing diagnosis and guiding treatment.

show abstract

mentioning

confidence: 99%

Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis

Ascierto

Bifulco

Palmieri

et al. 2019

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

“…Liquid biopsy techniques detect these different blood-based biomarkers including circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), also known as cfDNA, circulating RNA (cfRNA), and exosomes. [ 6 ]…”

Section: Components Of Liquid Biopsymentioning

confidence: 99%

“…The first and foremost step in attaining valuable information pertaining to cancer treatment is efficient isolation of CTC, cfDNA, and cfRNA shed by the tumour cells, which are very few in amount, in order to gain information and increase sensitivity and specificity. [ 6 ] Molecular analysis should be performed, followed by isolation; it includes fluorescence in situ hybridisation (FISH), microarray, sequencing, immunofluorescence, flow cytometry, and reverse-transcriptase PCR (RT-PCR). Digital PCR comprising droplet-based systems (ddPCR), microfluidic platforms for parallel PCR, NGS, BEAMing (Beads, Emulsions Amplification and Magnetics), and amplification-refractory mutation system (Scorpion-ARMS) assay are additional techniques that can also be considered.…”

Section: Analysis Of Liquid Biopsymentioning

confidence: 99%

“…Digital PCR comprising droplet-based systems (ddPCR), microfluidic platforms for parallel PCR, NGS, BEAMing (Beads, Emulsions Amplification and Magnetics), and amplification-refractory mutation system (Scorpion-ARMS) assay are additional techniques that can also be considered. [ 6 ]…”

Section: Analysis Of Liquid Biopsymentioning

confidence: 99%

“…Capture of CTCs, ctDNA, and exosomes as a “liquid biopsy” has several promising advantages over standard biopsy pertinent to clinical settings [ Figure 3 ]. [ 6 8 ]…”

Section: Clinical Applications Of Liquid Biopsymentioning

confidence: 99%

See 2 more Smart Citations

Liquid biopsy and its significance in tumour – detection in the field of pathology

Grover

Tomar²,

Tomar

et al. 2023

J Oral Maxillofac Pathol

View full text Add to dashboard Cite

The treatment of cancer has remarkably improved because of increased knowledge of the abnormalities at the molecular level, which results in human cancer growth. This has initiated the development of ever more successful as well as effective targeted cancer therapies. Detection of cancer is diagnosed basically by performing routine biopsy/cytology, which has many drawbacks. Therefore, the concept of liquid biopsy has been introduced to oncology, which has the potential to revolutionise the management of cancer patients, eliminating the invasive procedures needed to obtain tissue samples and provide information. Liquid biopsy is the analysis of tumour cells or tumour cell products obtained from blood or other body fluids, providing a broad range of opportunities in the field of pathology. Here, we focus on the most prominent liquid biopsy markers, circulating tumour cells and circulating tumour-derived deoxyribonucleic acid (DNA), in the blood of patients. In this review, we discuss recent clinical studies on these biomarkers for early detection and prognostication of cancer, which helps in successful management. Hence, liquid biopsy is introduced with great promise for personalised medicine because of its ability to provide multiple non-invasive snapshots of the primary and metastatic tumours.

show abstract